| Follow–up | |||||
---|---|---|---|---|---|---|
Outcome | Short-term (0–1 year) | Medium-term (1–20 years) | Long-term (>20 years) | |||
 | % (95% CI) | Studies (I2 %) | % (95% CI) | Studies (I2 %) | % (95% CI) | Studies (I2 %) |
Survival | 92.0 (91.0–93.0) | 151 (85.8) | 90.0 (89.0–91.0) | 133 (84.1) | 87.0 (80.0–92.0) | 4 (84.5) |
Survival in the first era | 90.0 (89.0–92.0) | 62 (82.6) | 88.0 (87.0–90.0) | 70 (86.9) | 89.0 (80.0–95.0) | 3 (N/A) |
Survival in the second era | 93.0 (92.0–94.0) | 89 (86.3) | 93.0 (91.0–94.0 | 63 (78.1) | 81.0 (76.0–86.0) | 1 (N/A) |
Freedom from reoperation | 93.0 (91.0–95.0) | 43 (92.3) | 81.0 (78.0–84.0) | 110 (95.6) | 78.0 (69.0–86.0) | 6 (95.5) |
Freedom from reoperation in the first era | 96.0 (94.0–97.0) | 22 (89.4) | 83.0 (79.0–86.0) | 62 (95.6) | 75.0 (63.0–85.0) | 4 (94.9) |
Freedom from reoperation in the second era | 90.0 (85.0–94.0) | 21 (92.3) | 79.0 (74.0–84.0) | 48 (95.9) | 85.0 (82.0–87.0) | 2 (N/A) |
Aortic insufficiency | 4.0 (2.0–7.0) | 19 (96.2) | 22.0 (17.0–26.0) | 65 (96.9) | 29.0 (25.0–33.0) | 2 (N/A) |
Aortic insufficiency in the first era | 1.0 (0.0–5.0) | 11 (95.8) | 18.0 (12.0–25.0) | 30 (97.6) | 41.0 (35.0–48.0) | 1 (N/A) |
Aortic insufficiency in the second era | 9.0 (2.0–15.0) | 8 (94.2) | 25.0 (18.0–32.0) | 35 (95.9) | 19.0 (14.0–24.0) | 1 (N/A) |
Pulmonary stenosis | 5.0 (2.0–9.0) | 9(85.5) | 12.0 (10.0–15.0) | 54 (92.8) | 82.0 (77.0–86.0) | 1 (N/A) |
Pulmonary stenosis in the first era | 8.0 (3.0–15.0) | 2 (N/A) | 12.0 (9.0–16.0) | 28 (93.2) | —* | 0 (N/A) |
Pulmonary stenosis in the second era | 4.0 (1.0–8.0) | 7 (86.5) | 12.0 (8.0–17.0) | 26 (92.3) | 82.0 (77.0–86.0) | 1 (N/A) |
Coronary anomaly | 1.0 (0.0–4.0) | 5 (59.7) | 8.0 (5.0–11.0) | 37 (93.3) | 23.0 (16.0–31.0) | 2 (N/A) |
Coronary anomaly in the first era | 1.0 (0.0–3.0) | 1 (N/A) | 4.0 (2.0–6.0) | 16 (87.6) | --* | 0 (N/A) |
Coronary anomaly in the second era | 1.0 (0.0–5.0) | 4 (53.9) | 12.0 (7.0–18.0) | 21 (94.0) | 23.0 (16.0–31.0) | 2 (N/A) |
Neuropsychological outcome MDI z score ** | * | —* | −0.1 (−0.8–0.6) | 17 (0.0) | —* | —* |
Neuropsychological outcome MDI z score** in the first era | —* | —* | −0.0 (−0.9–0.8) | 10 (0.0) | —* | —* |
Neuropsychological outcome MDI z score** in the second era | —* | —* | −0.3 (−1.9–1.2) | 7 (0.0) | —* | —* |
Neuropsychological outcome PDI z score** | —* | —* | −0.3 (−1.3–0.7) | 11 (0.0) | —* | —* |
Neuropsychological outcome PDI z score** in the first era | —* | —* | −0.4 (−1.6–0.9) | 5 (0.0) | —* | —* |
Neuropsychological outcome PDI z score** in the second era | —* | —* | −0.3 (−1.9–1.3) | 6 (0.0) | —* | —* |
Quality of life | —* | —* | Assessed with 7 studies. Three studies found no difference in Health-Related Quality of Life (HRQoL) of ASO patients relative to the general population; two studies found that ASO patients had better HRQoL, while two others found they had lower HRQoL. | —* | —* |